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follow-up of the latter group will further define the role of TMR
in the treatment of an increasingly complex cardiac surgical
patient.
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REPLY
The letter by Dr. Allen and colleagues raises a number of
important issues. First, they point out that the operative risk
factors for transmyocardial revascularization (TMR) identified in
our study (1) were similar to those noted in earlier randomized
studies. Although we agree that the preoperative risk factors
identified were not unique, our study provided confirmatory
evidence as to their generalizability in a broader clinical practice
setting. More significantly, our national study demonstrated there
is still a need to optimize appropriate patient selection for the
procedure in contemporary care. Specifically, our study and others
clearly demonstrate the risks of TMR in patients with unstable
symptoms or recent myocardial infarction (MI). Despite this, we
found more than half of TMR cases done in community practice
were performed under these conditions. Thus, we believe it
valuable to re-emphasize to clinicians these potentially modifiable
operative risk factors as a means of encouraging safer use of TMR
in community practice in the future.
Dr. Allen and colleague’s second point was that we failed to
acknowledge the efficacy data for TMR-only. In this regard, we
would argue that our study did reference the six randomized
clinical trials that support the effectiveness of TMR-only to reduce
patient symptoms. The recent abstract on five-year results sited by
Allen was not available before our study’s publication, and we look
forward to seeing this work in press soon.
The third point raised by Dr. Allen and colleagues concerns the
role of TMR when used in conjunction with coronary artery bypass
graft (TMR  CABG). Our study confirms that this combined
procedure has become the dominant role for TMR in contempo-
rary practice. There is less compelling evidence for the efficacy of
TMR in this setting, however, than is found in TMR-only. The
sole randomized trial of TMR  CABG failed to identify a
significant reduction in angina symptoms, but it did report an
unexpected reduction in perioperative event rates (2). Our obser-
vational study could not confirm these promising findings when
comparing operative outcomes among patients with three-vessel
disease who got TMR CABG versus those receiving incomplete
revascularization with CABG-only (i.e., one or two grafts only).
We agree with Dr. Allen and colleagues that observational
treatment comparisons, even when risk-adjusted, may still be
challenged by unmeasured patient selection biases (a point we
included in our report).
In conclusion, our study emphasized the importance and utility
of clinical registry information in providing evidence to further
refine the optimal application of technology after its introduction
into clinical care. Its main goals were to describe contemporary
practice patterns; to improve the safety of the procedure through
appropriate patient selection; and to stimulate future research in
areas requiring further clarification. We hope we have accom-
plished these goals and that Dr. Allen and colleagues continue to
refine the optimal role for this procedure.
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Medical Malpractice
Insurance: A Multifaceted Problem
I laud Dr. DeMaria’s efforts in summarizing the issues surrounding
the medical malpractice crisis in the November issue of the Journal
(1). However, I am struck by the lack of courage of state medical
licensing boards in not advocating for stronger laws, policies, and
procedures to focus on the 5% of physicians responsible for 50%
malpractice payouts. Whereas the medical profession should be
commended for its patient safety efforts—“an ounce of prevention
is worth a pound of cure”—the community of physicians will not
achieve credibility with patients unless we begin to review cases of
those with the highest rates of payouts. If the medical profession
can demonstrate success in this area, then we will have every right
to demand that the insurance industry and malpractice lawyers
come to the table for broader, more comprehensive, and more
collaborative solutions to the medical malpractice crisis.
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